DAY 1 (3 November 2022) CONFERENCE PROGRAM


UNIVERSITY CLUB AUDITORIUM, University Club Western Australia.


8:00am – 8:30am      Registration and coffee
8:30am – 9:00am      Opening Session

8:30am – 8:40am      Welcome to Perth: Professor Peter Davies, PhD  
(Deputy Vice Chancellor- Research and Innovation, Murdoch University, Perth, Australia)


8:40am – 8:50am       Opening: Ralph Martins, PhD   
(Chair in Aging & Alzheimer’s Disease, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia)

8:50am – 9:00am       Steve Greenberg, MD, PhD 
(Professor of Neurology at Harvard Medical School, Boston, USA)


9:00am – 9:45am       Plenary Speech: Professor Colin L Masters MD 
(The FloreyProfessor Colin L Masters MD

Professor of Dementia Research, The Florey Institute, The University of Melbourne

Title of Speech
: “The spectrum of Alzheimer’s disease covers parenchymal and perivascular accumulation of beta amyloid”.

Professor Colin Masters has focused his career on research in Alzheimer’s disease and other neurodegenerative diseases, including Creutzfeldt-Jakob disease. His work over the last 40 years is widely acknowledged as having had a major influence on Alzheimer’s disease research world-wide, particularly the collaborative studies conducted with Konrad Beyreuther in which they discovered the proteolytic neuronal origin of the Aβ
amyloid protein which causes Alzheimer’s disease. This work has led to the continued development of diagnostics and therapeutic strategies. More recently, his focus has been on describing the natural history of Alzheimer’s disease as a necessary preparatory step for disease modifying therapies

Professor Masters is a Professor of Dementia Research at the Florey Institute, and the University of Melbourne and a consultant at the Royal Melbourne Hospital. His achievements have been recognised by the receipt of many international awards.


Contact Details

The Florey Institute of Neuroscience and Mental Health

30 Royal Parade, Parkville, VIC 3010 Australia

Ph: +613 9035 6575


 Institute of Neuroscience and Mental Health, Parkville, Australia)


Coffee break (15 min)


10:00am – 12.15pm   1. Theme (full session) ARIA/CAA-ri 
*Moderator: Darshan Ghia, MD, Fiona Stanley Hospital, Western Australia

  • Association of in-vivo microglial activation with MRI markers of CAA , CAAri, and CSF anti-amyloid autoantibody testing: 10 years experience of the iCAB longitudinal Cohort Registry on Spontaneous ARIA 
      – Fabrizio Piazza, PhD University of Milano Bicocca, Monza, Italy
  • Animal models for ARIA

  – Patricia Kelly, PhD, University of Ulster, Coleraine North Ireland

  • Modelling of MRI changes in ARIA 
      – Roxana Aldea, PhD, Roche, Basel, Switzerland

CAA related inflammation- an update  *Virtual
  – Ellis van Etten, MD PhD, Leiden University Medical Centre, Leiden, Netherlands

Selected Oral Abstracts
#1: E.A Koemans

Subarachnoid CSF hyperintensities at 7T FLAIR MRI: a potential marker of cerebral amyloid angiopathy
#2: V. Perosa (J.Rotta)   *Virtual
Detection of cerebral microbleeds using Quantitative Susceptibility Mapping at 7 Tesla MRI
#3: B.Sharma
Associations between Grey and White Matter Damage and Gait Impairment in Cerebral Amyloid Angiopathy

12:15pm – 1:15pm    Lunch break/Poster Viewing


1:15pm – 2.30pm     2a. Theme (half-session) Iatrogenic CAA
 *Moderator: Eric Smith, MD, University of Calgary, Canada

  • Acquired cerebral amyloid angiopathy: insight into molecular mechanisms  
      – Masahito Yamada, MD, PhD Kudanzaka Hospital, Tokyo, Japan 
  • Iatrogenic CAA: clinical and mechanistic implications 
      – Gargi Banerjee, PhD, UCL Institute of Prion Diseases, London, UK
  • Selected Oral Abstracts
  • #1: E. Chan.  *Virtual
    Domain-specific neuropsychological investigation of CAA with and without intracerebral haemorrhage 
  • #2: L. Liu
    Biodistribution and long-term effects of tranexamic acid in a mouse model of CAA

#3: M. Kozberg

Developing novel mouse models of CAA-related cortical superficial siderosis 

Coffee break (15 min)


  • 2.45pm – 5:00pm     2b. Theme (half-session) D-CAA: Progress to Treatment Trials
  • *Moderator: Hamid Sohrabi, PhDCentre for Healthy Ageing, Murdoch University, Western Australia
    • Developments in MRI biomarkers of (Dutch-CAA
        – Matthias van Osch, PhD, Leiden University Medical Center, Leiden, Netherlands
    • Dutch-type hereditary CAA: from TRACK D-CAA towards a clinical trial 
        – Marieke Wermer, MD, PhD, Leiden University Medical Center, Leiden, Netherlands
    • Biomarkers for CAA trials 
        – Steven Greenberg MD, PhD, Harvard Medical School, Boston, USA
    • The Family Perspective: The real power of your N
    •   –  Sanne van Rijn, Msc, Dorinda ‘t Hart, Msc, PhD, function representative families
  • Selected Oral Abstracts
  • #1: S. Pedrini
    Plasma and CSF biomarkers are altered in D-CAA mutant-carriers compared to non-carriers
    #2: S. Voigt
    Neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of CAA
    #3: M. Schipper
    Total White Matter Perivascular Space Volume: an early marker for Dutch-Type CAA

    5:00pm – 6:00pm     Poster Viewing 


6:30pm – 11:00pm    Conference Dinner and networking Event:

Mathilda Bay Restaurant
Catalina Room
3 Hackett Dr
Crawley WA 6009